Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Kingchem
301509
5
Hunan Er-kang Pharmaceutical
300267
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | -12.34%125.91M | -17.93%36.23M | -9.30%33.56M | -20.22%27.18M | 1.84%28.94M | -34.99%143.63M | -28.41%44.14M | -35.41%37M | -36.61%34.07M | -41.09%28.42M |
Operating revenue | -12.34%125.91M | -17.93%36.23M | -9.30%33.56M | -20.22%27.18M | 1.84%28.94M | -34.99%143.63M | -28.41%44.14M | -35.41%37M | -36.61%34.07M | -41.09%28.42M |
Cost of revenue | -20.56%70.19M | -34.94%17.15M | -28.14%16.56M | -21.05%16.47M | 10.60%20.01M | -33.53%88.36M | -22.76%26.37M | -29.46%23.05M | -44.57%20.86M | -36.52%18.09M |
Gross profit | 0.81%55.72M | 7.29%19.07M | 21.81%16.99M | -18.91%10.72M | -13.51%8.93M | -37.20%55.27M | -35.42%17.78M | -43.31%13.95M | -18.06%13.22M | -47.70%10.33M |
Operating expense | -35.47%46.65M | -39.31%8.73M | -51.46%8.94M | -32.06%13.3M | -21.25%15.69M | -49.67%72.29M | -59.54%14.38M | -49.40%18.42M | -46.76%19.57M | -42.98%19.92M |
Selling and administrative expenses | -36.89%42.95M | -41.37%7.83M | -53.73%8.03M | -33.08%12.38M | -21.91%14.7M | -45.99%68.05M | -56.95%13.36M | -45.60%17.36M | -42.74%18.51M | -38.75%18.82M |
-Selling and marketing expense | -48.28%12.55M | -53.63%9.22M | -35.64%910K | -35.91%1.14M | 7.55%1.28M | -52.16%24.26M | 50.65%19.88M | -89.20%1.41M | -84.86%1.77M | -90.63%1.19M |
-General and administrative expense | -30.57%30.4M | 78.73%-1.39M | -55.33%7.12M | -32.78%11.25M | -23.90%13.42M | -41.83%43.78M | -136.61%-6.53M | -15.30%15.95M | -18.78%16.73M | -2.12%17.63M |
Depreciation amortization depletion | -12.70%3.7M | -12.46%899K | -14.22%905K | -14.27%913K | -9.95%987K | -75.96%4.24M | -77.31%1.03M | -76.44%1.06M | -76.04%1.07M | -73.92%1.1M |
-Depreciation and amortization | -12.70%3.7M | -12.46%899K | -14.22%905K | -14.27%913K | -9.95%987K | -75.96%4.24M | -77.31%1.03M | -76.44%1.06M | -76.04%1.07M | -73.92%1.1M |
Operating profit | 153.29%9.07M | 204.77%10.34M | 280.30%8.05M | 59.42%-2.58M | 29.58%-6.75M | 69.41%-17.02M | 142.32%3.39M | 62.11%-4.47M | 69.21%-6.35M | 36.85%-9.59M |
Net non-operating interest income expense | 18.35%-14.67M | 38.38%-2.92M | 21.85%-3.16M | 15.04%-4.25M | -3.75%-4.34M | -57.20%-17.97M | -62.44%-4.74M | -26.95%-4.04M | -99.56%-5M | -48.30%-4.18M |
Non-operating interest expense | -18.35%14.67M | -38.38%2.92M | -21.85%3.16M | -15.04%4.25M | 3.75%4.34M | 57.20%17.97M | 62.44%4.74M | 26.95%4.04M | 99.56%5M | 48.30%4.18M |
Other net income (expense) | 10.80%-1.82M | 92.25%-77K | 63.51%-77K | 12.64%-76K | -113.02%-1.59M | -45.81%-2.04M | -98.40%-994K | 37.76%-211K | 32.03%-87K | -73.66%-745K |
Special income (charges) | 10.80%-1.82M | 92.25%-77K | 63.51%-77K | 12.64%-76K | -113.02%-1.59M | -45.81%-2.04M | -98.40%-994K | 37.76%-211K | 32.03%-87K | -73.66%-745K |
-Less:Restructuring and merger&acquisition | -69.01%313K | --0 | --0 | --0 | -37.27%313K | --1.01M | --541K | --60K | ---90K | --499K |
-Less:Impairment of capital assets | 906.72%1.2M | --0 | --0 | --0 | 906.72%1.2M | -53.70%119K | --0 | --0 | --0 | -53.70%119K |
-Less:Other special charges | -47.51%306K | -39.84%77K | -49.01%77K | -57.06%76K | -40.16%76K | -48.86%583K | -74.45%128K | -55.46%151K | 38.28%177K | -26.16%127K |
-Gain on sale of property,plant,equipment | --0 | ---- | ---- | ---- | ---- | ---325K | ---- | ---- | ---- | ---- |
Income before tax | 79.96%-7.42M | 413.93%7.35M | 155.25%4.82M | 39.66%-6.9M | 12.66%-12.68M | 45.92%-37.02M | 79.54%-2.34M | 43.05%-8.72M | 50.82%-11.44M | 21.25%-14.52M |
Income tax | 26.40%249K | 155.77%133K | -23.08%40K | -59.30%35K | 485.71%41K | 118.53%197K | -55.56%52K | -90.49%52K | 104.94%86K | -50.00%7K |
Net income | -81.19%-100.71M | 223.83%6.88M | 135.43%3.96M | 57.98%-8.19M | -433.41%-103.36M | 21.56%-55.58M | 59.44%-5.56M | 32.35%-11.17M | 12.26%-19.48M | -5.03%-19.38M |
Net income continuous Operations | 79.40%-7.67M | 401.55%7.21M | 154.47%4.78M | 39.81%-6.94M | 12.42%-12.72M | 44.78%-37.22M | 79.30%-2.39M | 44.69%-8.77M | 46.45%-11.53M | 21.27%-14.52M |
Net income discontinuous operations | -406.58%-93.04M | 89.44%-334K | 65.66%-822K | 84.30%-1.25M | -1,767.67%-90.64M | -429.31%-18.37M | -47.73%-3.16M | -270.59%-2.39M | -1,065.01%-7.96M | ---4.85M |
Minority interest income | ||||||||||
Net income attributable to the parent company | -81.19%-100.71M | 223.83%6.88M | 135.43%3.96M | 57.98%-8.19M | -433.41%-103.36M | 21.56%-55.58M | 59.44%-5.56M | 32.35%-11.17M | 12.26%-19.48M | -5.03%-19.38M |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | -81.19%-100.71M | 223.83%6.88M | 135.43%3.96M | 57.98%-8.19M | -433.41%-103.36M | 21.56%-55.58M | 59.44%-5.56M | 32.35%-11.17M | 56.13%-19.48M | -5.03%-19.38M |
Basic earnings per share | -14.46%-2.85 | 177.78%0.14 | 123.40%0.11 | 68.18%-0.28 | -275.96%-3.91 | 38.06%-2.49 | 76.00%-0.18 | 47.78%-0.47 | 27.87%-0.88 | 13.33%-1.04 |
Diluted earnings per share | -14.46%-2.85 | 177.78%0.14 | 123.40%0.11 | 68.18%-0.28 | -275.96%-3.91 | 38.06%-2.49 | 76.00%-0.18 | 47.78%-0.47 | 27.87%-0.88 | 13.33%-1.04 |
Dividend per share | ||||||||||
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- |